Royalty Pharma to Discuss Portfolio Strategy at Goldman Sachs Healthcare Conference
Event summary
- Royalty Pharma will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 4:00 p.m. ET.
- The webcast will be accessible from Royalty Pharma’s “Events” page and archived for at least 30 days.
- Royalty Pharma manages royalties on over 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, and Roche’s Evrysdi.
- The company funds innovation through partnerships with biotech firms and acquisitions of existing royalties.
The big picture
Royalty Pharma’s participation in the Goldman Sachs Healthcare Conference underscores its role as a key player in biopharmaceutical financing. The company’s strategy of acquiring and funding royalties on leading therapies positions it uniquely in an industry increasingly reliant on innovative funding models. With a portfolio spanning major pharmaceutical products, Royalty Pharma’s approach could set a precedent for how biotech innovation is financed in the future.
What we're watching
- Portfolio Performance
- How Royalty Pharma’s focus on top-line sales-based royalties will impact its financial stability amid market volatility.
- Strategic Partnerships
- Whether Royalty Pharma can sustain its collaborative model with leading pharmaceutical companies to drive future growth.
- Innovation Funding
- The pace at which Royalty Pharma can fund late-stage clinical trials and new product launches through its royalty model.